TechDogs-"Kognitic's AI Model Revolutionizes Primary Completion Date Predictions For Clinical Trials"

Pharmaceutical Technology

Kognitic's AI Model Revolutionizes Primary Completion Date Predictions For Clinical Trials

By PR Newswire

PR Newswire
Overall Rating

A newly published study shows Kognitic's AI reduces clinical trial primary completion date prediction errors from 508 to 179 days, transforming pharmaceutical planning accuracy.

SOMERVILLE, N.J., Jan. 13, 2025 /PRNewswire/ -- A study published in Foresight demonstrates that Kognitic's neural network model significantly outperforms traditional methods in predicting primary completion dates (PCD) for clinical trials, potentially saving pharmaceutical companies millions in development costs. The research shows that sponsors' initial PCD estimates deviate by a median of 508 days, while Kognitic's AI model reduces this error to just 179 days.

The study, titled "Neural Network Models to Predict Clinical Trial Completion," details how the model analyzes data from over 60,000 oncology clinical trials to provide more accurate PCD predictions. This breakthrough has significant implications for drug development, where PCD delays can cost pharmaceutical companies between $600,000 to $8 million per day.

Several leading pharmaceutical companies have integrated Kognitic's PCD prediction model into their competitive intelligence and timeline management processes through SaaS subscriptions. The platform helps these companies make informed decisions about drug development strategies and anticipate competitors' market entry timing.

The research, published in Foresight's Q1 2025 edition, shows how the model incorporates multiple factors—indication, phase, line of therapy, population, biomarker, and other trial characteristics—to generate predictions. This sophisticated analysis enables pharmaceutical companies to set realistic timelines and manage drug development resources more effectively.

Key findings:

  • Reduces timeline prediction error from the industry standard of 508 days to 179 days, enabling better resource planning and cost management.
  • Analyzes a comprehensive dataset of 60,000+ oncology trials to deliver data-driven insights for trial design and execution.
  • Empowers pharmaceutical companies to avoid costly delays with precise competitive intelligence, resource planning, and market-entry timing.

Who benefits: Competitive intelligence, R&D, BD, and commercial groups looking to optimize planning, especially as 2025 strategies take shape.

For more information or to book a demo, visit kognitic.com or email info@kognitic.com.

About Kognitic:

Kognitic is a SaaS-based predictive intelligence platform revolutionizing how pharmaceutical and biotech companies approach competitive intelligence and business development. Using advanced machine learning and natural language processing, Kognitic delivers real-time, actionable insights from clinical trials, drug pipelines, and market dynamics. Top pharmaceutical companies rely on Kognitic's AI-powered analytics to transform weeks of analysis into minutes of intelligence.

Media Contact: info@kognitic.com

View original content:https://www.prnewswire.com/news-releases/kognitics-ai-model-revolutionizes-primary-completion-date-predictions-for-clinical-trials-302348567.html

SOURCE Kognitic

First published on Tue, Jan 14, 2025

Enjoyed what you read? Great news – there’s a lot more to explore!

Dive into our content repository of the latest tech news, a diverse range of articles spanning introductory guides, product reviews, trends and more, along with engaging interviews, up-to-date AI blogs and hilarious tech memes!

Also explore our collection of branded insights via informative white papers, enlightening case studies, in-depth reports, educational videos and exciting events and webinars from leading global brands.

Head to the TechDogs homepage to Know Your World of technology today!

Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.

Join The Discussion

- Promoted By TechDogs -

Join Our Newsletter

Get weekly news, engaging articles, and career tips-all free!

By subscribing to our newsletter, you're cool with our terms and conditions and agree to our Privacy Policy.

  • Dark
  • Light